March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Development Of Single Step Nano-Optical Immunoassay As A Replacement For ELISA For The Measurement of Protein Biomarkers Upregulated in Disease State
Author Affiliations & Notes
  • Shradha V. Prabhulkar
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • Adam de la Zerda
    Electrical Engineering and Radiology,
    Stanford University, Palo Alto, California
  • Sanjiv Gambhir
    Bioengineering & Materials Science and Engineering,
    Stanford University, Palo Alto, California
  • Richard Awdeh
    Bascom Palmer Eye Institute, University of Miami, Miami, Florida
  • Footnotes
    Commercial Relationships  Shradha V. Prabhulkar, None; Adam de la Zerda, None; Sanjiv Gambhir, None; Richard Awdeh, None
  • Footnotes
    Support  NIH/ NEI R21 – EY020940
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 332. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shradha V. Prabhulkar, Adam de la Zerda, Sanjiv Gambhir, Richard Awdeh; Development Of Single Step Nano-Optical Immunoassay As A Replacement For ELISA For The Measurement of Protein Biomarkers Upregulated in Disease State. Invest. Ophthalmol. Vis. Sci. 2012;53(14):332.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : This study focuses on the development of a rapid single-step, highly sensitive immunoassay for the measurement of protein biomarkers with a wide detection range. Gold nanorods (GNRs) were used as the signaling labels, as they are not affected by reagent chemistry or photobleaching, and exhibit unique optical properties such as tunable enhanced scattering/absorption of light and biocompatibility. Optical coherence tomography (OCT) was chosen as the tool to detect the GNR labels, utilizing their high scattering properties.

Methods: : GNRs [size:15X60nm, SPR:840nm] were covalently attached to Glut-1 specific monoclonal antibodies via carbodiimide chemistry. Glut-1 protein (model analyte) was directly attached to the surface of micto-titter plates by overnight incubation at 4oC. The Glut-1 monoclonal antibody functionalized GNRs were then allowed to incubate within the wells for 60 minutes at room temperature. The wells were then twice-rinsed with 1X PBS buffer to remove any unbound GNRs. 100µl of pH = 14, 1X PBS buffer was then infused into each well and the plates were sonicated for 45 minutes. The sonication and alkaline buffer causes the protein and gold nanorod conjugate to break up and float freely in the buffer solution. OCT imaging of the sonicated immunoassay plates containing functionalized GNRs + bound analyte dispersed in PBS solution was conducted using the Bioptigen Spectral Domain Ophthalmic Imaging System (SDOIS). A calibration curve was obtained by plotting the concentration of the Glut-1 protein initially incubated in each well versus the average signal intensity obtained from normalized OCT images.

Results: : Our detection range using this nano-optical immunoassay was wide, ranging from 10ng/ml to 1ug/ml. The minimal detectable concentration based on the intercept of our calibration curve of Glut-1 was 2.8ng/ml.

Conclusions: : This novel nano-optical immunoassay holds promise to act as a simple, selective, sensitive strategy for effective disease diagnosis, and offers advantages over traditional ELISA techniques, such as wide detection range, increased speed of analysis (due to fewer incubation/washing steps), and no label development required. Our future goal is to incorporate this strategy onto a microfluidic platform to be used as a point-of-care diagnostic tool.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • protein purification and characterization • oncology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.